Kini-3 motor protein and methods for its use

Abstract

The invention provides isolated nucleic acid and amino acid sequences of KinI-3, antibodies to KinI-3, methods of screening for KinI-3 modulators using biologically active KinI-3, and kits for screening for KinI-3 modulators.

1 - 19  (Canceled)  
     
     
         20 . A method of expression monitoring comprising: 
 (a) providing a population of mRNA; and    (b) hybridizing the population or an amplification product thereof to a probe comprising at least 15 contiguous nucleotides of SEQ ID NO:1, or its perfect complement or a degenerate form of either of these;    (c) detecting hybridization to monitor expression of mRNA in the population complementary to the probe.    
     
     
         21 . The method of  claim 20 , wherein the probe is part of an array of probes.  
     
     
         22 . The method of  claim 20 , wherein the amplification product is cDNA.  
     
     
         23 . The method of  claim 21 , wherein the array further comprises probes from other kinesin genes and/or from genes having roles in replication or cell division.  
     
     
         24 . The method of  claim 20 , wherein the mRNA population is from a tissue in a disease state.  
     
     
         25 . The method of  claim 20 , further comprising repeating the method for a second mRNA population or an amplification product thereof to identify an mRNA that is differentially expressed between the mRNA population and the second mRNA population.  
     
     
         26 . The method of  claim 20 , wherein the probe comprises at least 20 contiguous nucleotides of SEQ ID NO:1, or its perfect complement or a degenerate form thereof.  
     
     
         27 . The method of  claim 20 , wherein the probe comprises at least 20 contiguous nucleotides of SEQ ID NO:1, or its perfect complement or a degenerate form thereof.  
     
     
         28 . The method of  claim 20 , wherein the mRNA population is from cancerous tissue.  
     
     
         29 . The method of  claim 25 , wherein the mRNA population is from cancerous tissue and the second mRNA population is from normal tissue adjacent the cancerous tissue.  
     
     
         30 . The method of  claim 28 , wherein the cancerous tissue is from a human patient.  
     
     
         31 . An isolated nucleic acid comprising at least 15 contiguous nucleotides of SEQ ID NO:1 or its perfect complement or a degenerate form thereof.  
     
     
         32 . The isolated nucleic acid of  claim 31  comprising at least 20 contiguous nucleotides of SEQ ID NO:1 or its perfect complement or a degenerate form thereof.  
     
     
         33 . The isolated nucleic acid of  claim 31  comprising at least 50 continguous nucleotides of SEQ ID NO:1 or its perfect complement or a degenerate form thereof.  
     
     
         34 . The isolated nucleic acid of  claim 31  comprising at least 100 contiguous nucleotides of SEQ ID NO:1 or its perfect complement or a degenerate form thereof.